iSKID: From integrated pilot scale runs to GMP implementation approach by Orozco, Raquel et al.
ISKID: FROM INTEGRATED PILOT SCALE RUNS TO GMP IMPLEMENTATION APPROACH 
 
Raquel Orozco, Boehringer Ingelheim, USA 
raquel.orozco@boehringer-ingelheim.com 
Scott Godfrey, Boehringer Ingelheim, USA 
Daisie Ogawa, Boehringer Ingelheim, USA 
Aaron Kwong, Boehringer Ingelheim, USA 
Joelle Koury, Boehringer Ingelheim, USA 
Charles Capron, Boehringer Ingelheim, USA 
Zack Kyser, Boehringer Ingelheim, USA 
Matt Brown, Boehringer Ingelheim, USA 
Eike Zimmerman, Boehringer Ingelheim, USA 
Jon Coffman, Boehringer Ingelheim, USA 
Jeff Salm, Pfizer, USA 
Rob Fahrner, Pfizer, USA 
Robert Kottmeier, Pfizer, USA 
Matt Stork, Pfizer, USA 
Mike Jankowski, Pfizer, USA 
 
 
One of the most compelling business reasons for integrated processing is the ability to de-risk capital 
investment due to a significantly more productive process that takes less space and fewer campaigns to 
generate clinical and commercial material. Boehringer Ingelheim and Pfizer developed the iSKID, a fully 
integrated and automated system that hydraulically links the perfusion bioreactor with several downstream unit 
operations (2xProtein A columns, continuous viral inactivation, AEX in flow through mode, and SPTFF). The 
Protein A elution cycles are discrete and separated by >2hrs, allowing the ability to discard cycles that do not 
meet process specifications. The discreteness between product cycles and hydraulic linkage enables the 
sanitization between cycles for a robust bioburden control strategy.  Each cycle is captured in a single use mixer 
(SUM), where the product is pooled in stable conditions until viral filtration, ultrafiltration/diafiltration and final 
filtration are performed in batch mode.  
 
Identical iSKID prototypes at 100L scale were used at three different sites to generate product quality, process, 
and bioburden data from three different molecules. The data has been used to understand implementation gaps 
in GMP facilities and process platforms (CMC1/CMC2). In addition, the team identified specific items to present 
to the FDA’s Emerging Technology Team (ETT). These items include our strategies for batch definition, 
microbial control, and process control. In this talk, we will use the data generated from the consistency runs to 
elaborate on the robustness of the process and touch upon the strategies to be presented to the ETT.     
 
